2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 891

A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Abstract Number: 890

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Abstract Number: 2510

A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Abstract Number: 1365

A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis
Abstract Number: 1938

A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Abstract Number: 971

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Abstract Number: 1850

A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Abstract Number: 2935

A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Abstract Number: 714

A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 1277

A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
Abstract Number: 2853

A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
Abstract Number: 244

A Qualitative Study Mapping the Behaviour Change Techniques Used in a Practice-Based Fibromyalgia Self-Management Programme
Abstract Number: 1243

A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Abstract Number: 1429

A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
Abstract Number: L18

A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab

« Previous Page
1
…
3
4
5
6
7
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].